• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ALENDRONIC ACID Drug Record

  • Summary
  • Interactions
  • Claims
  • ALENDRONIC ACID chembl:CHEMBL870 Approved

    Alternate Names:

    BINOSTO
    ALENDRONIC ACID
    ALENDRONATE
    FOSAMAX
    ACIDO ALENDRONICO
    (4-AMINO-1-HYDROXYBUTYLIDENE)BISPHOSPHONIC ACID
    FOSAMAX®
    G-704650
    ACIDUM ALENDRONICUM
    BPH 1
    ABDP
    MK-217
    ACIDE ALENDRONIQUE
    (4-AMINO-1-HYDROXYBUTANE-1,1-DIYL)BIS(PHOSPHONIC ACID)
    4-AMINO-1-HYDROXYBUTANE-1,1-DIPHOSPHONIC ACID
    drugbank:00630
    rxcui:236083
    chemidplus:66376-36-1
    chembl:CHEMBL870
    rxcui:46041
    pubchem.compound:2088

    Drug Info:

    Drug Class bisphosphonates
    Year of Approval 1995
    FDA Approval 1995
    Drug Class small molecule
    Drug Indications Bisphosphonates
    (3 More Sources)

    Publications:

    Heikkilä et al., 2002, Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines., Anticancer Drugs
    Engel et al., 2003, Alendronate and etidronate do not regulate interleukin 6 and 11 synthesis in normal human osteoblasts in culture., Calcif. Tissue Int.
    Wang C et al., 2015, Genetic polymorphisms in the mevalonate pathway affect the therapeutic response to alendronate treatment in postmenopausal Chinese women with low bone mineral density., Pharmacogenomics J
    Palomba et al., 2003, Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes., Clin. Endocrinol. (Oxf)
    Mossetti G et al., 2008, Vitamin D receptor gene polymorphisms predict acquired resistance to clodronate treatment in patients with Paget's disease of bone., Calcif Tissue Int
    Otrock ZK et al., 2008, Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis., Ann Hematol
    Palomba S et al., 2005, BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial., Osteoporos Int
    Tofteng CL et al., 2002, Two polymorphisms in the vitamin D receptor gene--association with bone mass and 5-year change in bone mass with or without hormone-replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study., J Bone Miner Res
    Arai H et al., 2001, The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene., J Bone Miner Res
    Marc J et al., 1999, VDR genotype and response to etidronate therapy in late postmenopausal women., Osteoporos Int
    Yamamoto H et al., 1999, The caudal-related homeodomain protein Cdx-2 regulates vitamin D receptor gene expression in the small intestine., J Bone Miner Res
    Creatsa M et al., 2011, The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study., J Obstet Gynaecol Res
    Lambrinoudaki I et al., 2011, BsmI vitamin D receptor's polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy., Eur J Neurol
    Hubner RA et al., 2008, Dairy products, polymorphisms in the vitamin D receptor gene and colorectal adenoma recurrence., Int J Cancer
    d'Alésio A et al., 2005, Two single-nucleotide polymorphisms in the human vitamin D receptor promoter change protein-DNA complex formation and are associated with height and vitamin D status in adolescent girls., Hum Mol Genet
    International HapMap Consortium., 2003, The International HapMap Project., Nature
    Tjernberg A et al., 2004, Mechanism of action of pyridazine analogues on protein tyrosine phosphatase 1B (PTP1B)., Bioorg Med Chem Lett
    Maffei et al., 2004, Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment., J. Clin. Endocrinol. Metab.
  • ALENDRONIC ACID   MVK

    Interaction Score: 15.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25223561


    Sources:
    PharmGKB

  • ALENDRONIC ACID   PTPN4

    Interaction Score: 7.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TEND

  • ALENDRONIC ACID   IL11

    Interaction Score: 2.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12522661


    Sources:
    NCI

  • ALENDRONIC ACID   FDPS

    Interaction Score: 1.93

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TEND TTD

  • ALENDRONIC ACID   PTPRC

    Interaction Score: 1.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15012988


    Sources:
    DTC

  • ALENDRONIC ACID   PLAU

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11984068


    Sources:
    NCI

  • ALENDRONIC ACID   CYP19A1

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14715828


    Sources:
    NCI

  • ALENDRONIC ACID   VDR

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12608943 19020788 18443790 15739035 12162507 11450701 10692979 9933478 21651652 20500803 18470879 16210379 14685227


    Sources:
    NCI PharmGKB

  • TEND: ALENDRONATE

    • Version: 01-August-2011

    Alternate Names:
    ALENDRONATE Primary Drug Name

    Drug Info:
    Year of Approval 1995
    Drug Class bisphosphonates

    Publications:

  • TdgClinicalTrial: ALENDRONATE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Bisphosphonates
    Drug Class small molecule
    FDA Approval 1995

    Publications:

  • NCI: ALENDRONATE

    • Version: 14-September-2017

    Alternate Names:
    C973 NCI drug code

    Drug Info:

    Publications:
    Heikkilä et al., 2002, Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines., Anticancer Drugs
    Engel et al., 2003, Alendronate and etidronate do not regulate interleukin 6 and 11 synthesis in normal human osteoblasts in culture., Calcif. Tissue Int.
    Palomba et al., 2003, Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes., Clin. Endocrinol. (Oxf)

  • DTC: ALENDRONIC ACID

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL870 ChEMBL Drug ID

    Drug Info:

    Publications:
    Tjernberg A et al., 2004, Mechanism of action of pyridazine analogues on protein tyrosine phosphatase 1B (PTP1B)., Bioorg Med Chem Lett

  • PharmGKB: alendronate

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Hubner RA et al., 2008, Dairy products, polymorphisms in the vitamin D receptor gene and colorectal adenoma recurrence., Int J Cancer
    Marc J et al., 1999, VDR genotype and response to etidronate therapy in late postmenopausal women., Osteoporos Int
    Creatsa M et al., 2011, The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study., J Obstet Gynaecol Res

  • TTD: Alendronate

    • Version: 2020.06.01

    Alternate Names:
    D09KLR TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL870

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21